[HTML][HTML] Primary pulmonary artery angiosarcoma mimicking pulmonary embolism in a 66-year-old man with dyspnea
P Desmarais, M Laskine, C Caporuscio - CMAJ, 2016 - Can Med Assoc
Discussion Pulmonary embolism is a frequently encountered condition. Its incidence, although
difficult to evaluate, has been estimated to be 112.3 cases per 100 000 adults annually …
difficult to evaluate, has been estimated to be 112.3 cases per 100 000 adults annually …
Oral delivery of highly lipophilic poorly water-soluble drugs: spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 …
…, K Stefanski, H Shen, C Huang, C Caporuscio… - Journal of …, 2014 - Elsevier
BMS-B is a highly lipophilic compound (clog P 7.72) with poor aqueous solubility (<10 ng/mL
at pH 1 and 6.5). The compound exhibits low bioavailability in preclinical species when …
at pH 1 and 6.5). The compound exhibits low bioavailability in preclinical species when …
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate
…, MJ Cullen, H Zhang, C Caporuscio… - Journal of medicinal …, 2014 - ACS Publications
Identification of MCHR1 antagonists with a preclinical safety profile to support clinical
evaluation as antiobesity agents has been a challenge. Our finding that a basic moiety is not …
evaluation as antiobesity agents has been a challenge. Our finding that a basic moiety is not …
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies
…, S Harvey, MJ Cullen, H Zhang, C Caporuscio… - Bioorganic & Medicinal …, 2015 - Elsevier
Non-basic azolotriazinones were explored using an empirical free brain exposures-driven
approach to identify potent MCHR1 antagonists for evaluation in in vivo efficacy studies. An …
approach to identify potent MCHR1 antagonists for evaluation in in vivo efficacy studies. An …
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup
…, S Harvey, MJ Cullen, H Zhang, C Caporuscio… - Bioorganic & Medicinal …, 2015 - Elsevier
Our investigation of the structure–activity and structure–liability relationships for
dihydropyrrolopyrazol-6-one MCHR1 antagonists revealed that off-rate characteristics, inferred from …
dihydropyrrolopyrazol-6-one MCHR1 antagonists revealed that off-rate characteristics, inferred from …
[PDF][PDF] VOLUME 9 SPRING 2013 NUMBER 3
…, P Anderson, E Barber, D Brodian, K Caporuscio… - Journal of Law …, 2013 - jlep.net
KAREN CZARNECKI: Symposium on Civil Justice Issues at George Mason University. I will
do some brief introductions of the staff who are here. I’ll give you some housekeeping items …
do some brief introductions of the staff who are here. I’ll give you some housekeeping items …
Mammalian cell culture on poly (dimethyl siloxane) functionalized for covalent immobilization of extracellular matrix-derived proteins
JM Lavoie - 2008 - escholarship.mcgill.ca
Tissue engineering is a wide, fast-expanding field. It relies on the extraction of cells from a
donor, their expansion and subsequent combination with a scaffold to be implanted in a …
donor, their expansion and subsequent combination with a scaffold to be implanted in a …
Evaluation of Nuclear Spent Fuel Disposal in Clay-Bearing Rock-Process Model Development and Experimental Studies
…, P Fox, T Sasaki, J Birkholzer, FA Caporuscio… - 2020 - osti.gov
The DOE R&D program under the Spent Fuel Waste Science Technology (SFWST)
campaign has made key progress in modeling and experimental approaches towards the …
campaign has made key progress in modeling and experimental approaches towards the …
Evolution of nonbasic thienopyrimidinone containing alcohols as selective MCHR1 antagonists culminating in the discovery of the clinical candidate BMS-830216
…, MJ Cullen, S Taylor, H Zhang, C Caporuscio… - 2012 - dro.deakin.edu.au
… posted on 2024-04-08, 05:21 authored by William N Washburn, Mark Manfredi, Pratik
Devasthale, Guohua Zhao, Saleem Ahmad, Andres Hernandez, Jeffrey A Robl, Wei Wang …
Devasthale, Guohua Zhao, Saleem Ahmad, Andres Hernandez, Jeffrey A Robl, Wei Wang …
A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 …
G Gasparini, P Canepa, S Verdiani… - International …, 2021 - journals.sagepub.com
Background Hypercoagulability is a risk factor of thromboembolic events in COVID-19. Anti-phospholipid
(aPL) antibodies have been hypothesized to be involved. Typical COVID-19 …
(aPL) antibodies have been hypothesized to be involved. Typical COVID-19 …
